Tamtam Try Tamtam free
Boston Scientific logo

Boston Scientific account plan

global medical technology leader

At a glance

Boston Scientific develops and sells medical devices for cardiovascular, GI, urology and neuromodulation care in 127 countries; FY2025 sales $20,074 million.

Boston Scientific, headquartered in Marlborough, Massachusetts, develops, manufactures and markets mostly single-use medical devices for less-invasive treatment of cardiovascular, respiratory, digestive, oncological, neurological and urological diseases. It sells to hospitals, clinics, outpatient facilities and medical offices in 127 countries, with large group purchasing organizations and hospital networks a substantial portion of sales. FY2025 net sales were $20,074 million (+19.9% reported, +15.8% organic) and GAAP net income attributable to common stockholders $2,898 million. It had approximately 59,000 employees at 31 December 2025, approximately 60 percent outside the U.S.

Business units

Strategic priorities

Five strategic imperatives
Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities.
Launch pipeline for 2028
Management lists seven new launches exceeding about a $25 billion TAM in 2028, including coronary IVL (H1 2027), TIVUS renal denervation, Penumbra, ICE imaging, FARAWAVE Ultra, the potential MiRus TAVR acquisition and circulatory support.
Recovering EP and WATCHMAN growth
The company is investing in physician education, commercial coverage and direct-to-patient programmes for WATCHMAN, and plans FARAWAVE Ultra and ICE entry in H2 2027 and FARAFLEX in 2028 for EP.
New operating structure
From 1 January 2027 three reportable segments (Interventional Therapies, Rhythm Solutions and MedSurg) replace the current two, under new COO Joseph M. Fitzgerald, to enable faster decision making.
Cost savings to reinvest in growth
The 2026 Restructuring Plan targets about $500 million a year of gross pre-tax savings by end-2029, with a substantial portion reinvested in growth initiatives.

Latest results

In Q2 2026 (quarter ended 30 June 2026) net sales were $5,442 million, +7.5% reported and +7.0% organic, and adjusted EPS was $0.86 (+14.6%); gross margin rose to 70.7%. Growth came mainly from ICVT and Electrophysiology, while increased EP competition and slower WATCHMAN procedures held sales back. On 29 July 2026 the company cut its full-year 2026 guidance to 5% to 6% organic growth and adjusted EPS of $3.28 to $3.32. A cybersecurity incident identified on 25 August 2026 then disrupted manufacturing and order shipping globally, and the company said it is unlikely to meet its Q3 and full-year guidance.

Investments and deals

Penumbra acquisition
Agreed on 15 January 2026 at $374 per share, approximately $14.500 billion, adding computer-assisted vacuum thrombectomy; stockholders approved it on 6 May 2026 and closing is expected in the second half of 2026 subject to regulatory clearance.
MiRus TAVR option
A $1.500 billion payment on 15 May 2026 bought about 33.75% of MiRus LLC, with an exclusive option to buy its SIEGEL TAVR business for a further $3.000 billion once milestones are met.
Tuck-in acquisitions
Bolt Medical, SoniVie, Cortex and Intera were acquired in 2025 ($1.593 billion), and Nalu Medical in January 2026 for approximately $517 million.
2026 Restructuring Plan
Approved on 21 July 2026: supply chain optimization including production line transfers and functional transformation, with $700-800 million of pre-tax charges through end-2029.
Share repurchases
The buyback authorization was raised to $5.000 billion and a $2.000 billion accelerated repurchase retired about 40 million shares.

Challenges and risks

Cybersecurity incident
Unauthorized activity identified on 25 August 2026 caused a global network outage that hit manufacturing, order processing and shipping; the timeline for full recovery was uncertain at the 8-K filing.
Competition in pulsed field ablation
Management did not anticipate the degree of competitive share movement in U.S. EP, where PFA is approximately 80% of the AFib market.
WATCHMAN referral slowdown
Clinical evidence from trials such as OCEAN and CLOSURE has reduced referrals for standalone procedures, with a new competitor expected in 2027.
Pricing and procurement pressure
Health care consolidation, national tenders and volume-based procurement in China weigh on pricing, notably in stone management.
Tariffs and supply chain
The company cites tariff uncertainty, higher distribution costs, single-source components and sterilization capacity as risks.

What leadership says

“This update today is not the outcome we planned or what you've come to expect from us.”

Mike Mahoney, Chairman and Chief Executive Officer · Q2 2026 earnings call, 29 July 2026, on the guidance cut

“In 2025, we achieved over $20 billion in sales and for the second year in a row, delivered mid-teens growth”

Mike Mahoney, Chairman and Chief Executive Officer · Q4 2025 earnings call, 4 February 2026

“These changes reflect the scale and breadth of our business today and the opportunities ahead.”

Mike Mahoney, Chairman and Chief Executive Officer · Press release on the new operating structure, 7 October 2026

Where a supplier can help

Cyber resilience and IT recovery
The August 2026 cybersecurity incident that halted manufacturing and shipping makes security, OT protection, backup and recovery offers directly relevant.
Supply chain and manufacturing transfers
The 2026 Restructuring Plan's production line transfers and supply chain optimization create needs for validation, automation and logistics partners.
Penumbra integration
Integrating a roughly $14.500 billion acquisition into the new Interventional Therapies segment calls for systems, sales operations and change management support.
Physician education and patient demand
The WATCHMAN response relies on physician education and direct-to-patient investment, which suits medical education, digital marketing and patient engagement providers.
Clinical trial execution
A pipeline resting on trials such as FARADIGM, SIMPLIFY and STAR fits CRO, imaging core lab and trial technology services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Boston Scientific?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Boston Scientific

What does Boston Scientific do?

Boston Scientific develops, manufactures and markets medical devices, mostly single-use, for less-invasive treatment of cardiovascular, digestive, urological, neurological, oncological and respiratory conditions.

What was Boston Scientific's revenue in 2025?

Net sales were $20,074 million in FY2025, up 19.9% reported and 15.8% organic, with adjusted EPS of $3.06.

How many employees does Boston Scientific have?

Approximately 59,000 employees at 31 December 2025, approximately 60 percent outside the U.S.

Who leads Boston Scientific?

Mike Mahoney is Chairman and CEO and Jonathan Monson is CFO; Joseph M. Fitzgerald becomes Chief Operating Officer on 1 January 2027.

What is Boston Scientific's growth strategy?

It combines internal R&D with acquisitions such as Penumbra and Nalu, targets high-growth adjacencies and global expansion, and plans seven major launches by 2028.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)